Literature DB >> 22323347

Course of neuropsychiatric symptoms during a 4-year follow up in the REAL-FR cohort.

S Gonfrier1, S Andrieu, D Renaud, B Vellas, P H Robert.   

Abstract

INTRODUCTION: The multicenter PHRC REAL-FR cohort study was designed to follow community-dwelling patients with a diagnosis of Alzheimer's Disease. The present study describes the evolution of neuropsychiatric symptoms (NPS) over 4 years.
METHOD: 686 patients were recruited at baseline from 16 French clinical centers. 151 patients were followed over the 4-year interval with 5 Neuropsychiatric evaluations. Neuropsychiatric symptoms were assessed using the Neuropsychiatric inventory (NPI). NPS symptoms were divided into 4 subgroups according to the European Alzheimer Disease Consortium NPI analysis; psychotic subgroup (hallucinations, delusions), hyperactivity subgroup (agitation, aggression, euphoria, disinhibition, irritability, aberrant motor behavior), apathy subgroup (apathy, eating) and affective subgroup (depression, anxiety). Secondly we studied the evolution of the population divided in 4 groups: Apathy only, Hyperactivity only, both Apathy and Hyperactivity, no Apathy no Hyperactivity.
RESULTS: At baseline, 100 patients (66%) presented with one or more clinically significant NPI symptoms. This figure increased to 88% at the end of 4-year follow-up (Linear by linear chi square, p<0, 0012). Five NPI symptoms showed significant increases in prevalence: agitation (17,9 to 29,1%), apathy (43,0 to 62,9%) , disinhibition (2,6 to 14,6%), hallucination (2 to 4,6%) and aberrant motor behavior (13,9 to 29,1%). Prevalence of hyperactivity and apathy subgroups increased significantly during the follow-up while the prevalence of affective and psychotic subgroups did not. The number of patients with both apathy and hyperactivity increased (27% to 44%) during the follow-up period whereas the number of patients without these symptoms decreased (p = .009).
CONCLUSION: The present study shows that 2 types of symptoms increased primarily over time: Apathy and Hyperactivity. The coexistence of such opposite symptoms over time according to our result should be taken into consideration by clinicians treating those patients.

Entities:  

Mesh:

Year:  2012        PMID: 22323347     DOI: 10.1007/s12603-011-0147-9

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  28 in total

1.  Modeling caregiver adaptation over time: the longitudinal impact of behavior problems.

Authors:  J E Gaugler; A Davey; L I Pearlin; S H Zarit
Journal:  Psychol Aging       Date:  2000-09

Review 2.  Behavioral effects of current Alzheimer's disease treatments: a descriptive review.

Authors:  Jeffrey L Cummings; Joan Mackell; Daniel Kaufer
Journal:  Alzheimers Dement       Date:  2008-01       Impact factor: 21.566

3.  Behavioral and neuropsychiatric outcomes in Alzheimer's disease.

Authors:  Jeffrey L Cummings
Journal:  CNS Spectr       Date:  2005-11       Impact factor: 3.790

4.  A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease.

Authors:  David Craig; Ajay Mirakhur; Dominic J Hart; Stephen P McIlroy; A Peter Passmore
Journal:  Am J Geriatr Psychiatry       Date:  2005-06       Impact factor: 4.105

5.  Relatives of the impaired elderly: correlates of feelings of burden.

Authors:  S H Zarit; K E Reever; J Bach-Peterson
Journal:  Gerontologist       Date:  1980-12

6.  Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors.

Authors:  H Brodaty; B Draper; D Saab; L F Low; V Richards; H Paton; D Lie
Journal:  Int J Geriatr Psychiatry       Date:  2001-05       Impact factor: 3.485

7.  Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium.

Authors:  Philippe H Robert; Frans R J Verhey; E Jane Byrne; Catherine Hurt; Peter Paul De Deyn; Flavio Nobili; Roberta Riello; Guido Rodriguez; Giovanni B Frisoni; Magda Tsolaki; Nora Kyriazopoulou; Roger Bullock; Alistair Burns; Bruno Vellas
Journal:  Eur Psychiatry       Date:  2005-01-27       Impact factor: 5.361

8.  The sources of convergence between measures of apathy and depression.

Authors:  R S Marin; S Firinciogullari; R C Biedrzycki
Journal:  J Affect Disord       Date:  1993-05       Impact factor: 4.839

9.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

10.  The spectrum of behavioral changes in Alzheimer's disease.

Authors:  M S Mega; J L Cummings; T Fiorello; J Gornbein
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

View more
  14 in total

1.  Behavioral management in the person with dementia.

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2013-01       Impact factor: 4.075

Review 2.  Non-cognitive symptoms and related conditions in the Alzheimer's disease: a literature review.

Authors:  Francesco Raudino
Journal:  Neurol Sci       Date:  2013-03-31       Impact factor: 3.307

3.  Trajectories of neuropsychiatric symptoms over time in healthy volunteers and risk of MCI and dementia.

Authors:  Jeannie-Marie S Leoutsakos; Elizabeth A Wise; Constantine G Lyketsos; Gwenn S Smith
Journal:  Int J Geriatr Psychiatry       Date:  2019-09-02       Impact factor: 3.485

4.  Fatty acids rehabilitated long-term neurodegenerative: like symptoms in olfactory bulbectomized rats.

Authors:  Shlomo Yehuda; Sharon Rabinovitz
Journal:  J Neural Transm (Vienna)       Date:  2014-10-08       Impact factor: 3.575

Review 5.  Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia.

Authors:  Mehnaz Ahmed; Marlene Malik; Johannes Teselink; Krista L Lanctôt; Nathan Herrmann
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

6.  Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.

Authors:  Paul B Rosenberg; Lea T Drye; Anton P Porsteinsson; Bruce G Pollock; D P Devanand; Constantine Frangakis; Zahinoor Ismail; Christopher Marano; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Gregory Pelton; Peter V Rabins; Lon S Schneider; David M Shade; Daniel Weintraub; Jeffery Newell; Jerome Yesavage; Constantine G Lyketsos
Journal:  Int Psychogeriatr       Date:  2015-08-25       Impact factor: 3.878

7.  Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design.

Authors:  Maria Soto; Sandrine Andrieu; Fati Nourhashemi; Pierre Jean Ousset; Clive Ballard; Philippe Robert; Bruno Vellas; Constantine G Lyketsos; Paul B Rosenberg
Journal:  Int Psychogeriatr       Date:  2014-09-16       Impact factor: 3.878

Review 8.  Diagnosis and Management of Neuropsychiatric Symptoms in Alzheimer's Disease.

Authors:  David Wolinsky; Karina Drake; Jolene Bostwick
Journal:  Curr Psychiatry Rep       Date:  2018-10-27       Impact factor: 5.285

Review 9.  Grouping of behavioural and psychological symptoms of dementia.

Authors:  Rianne M van der Linde; Tom Dening; Fiona E Matthews; Carol Brayne
Journal:  Int J Geriatr Psychiatry       Date:  2013-10-16       Impact factor: 3.485

10.  Neuropsychiatric symptoms in patients with dementia in primary care: a study protocol.

Authors:  Petra Borsje; Roland B Wetzels; Peter L B J Lucassen; Anne-Margriet Pot; Raymond T C M Koopmans
Journal:  BMC Geriatr       Date:  2014-03-17       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.